[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Cases and deaths surge in Brazil", "description": "UK\n\nCases, + 3,862 (+ 37,487)\nDown 1.7%\n\nDeaths, + 19 (+ 437) = 126,593\nDown 31.7%\n\nHospitalised, + 343 = 4,560\n\nhttps://coronavirus.data.gov.uk\n\nPeople vaccinated up to and including 27 March 2021\nFirst dose: 30,151,287\nSecond dose: 3,527,481\nUS\n\nCases, +71,593 (+ 421,233) = 30,000,000\n\nhttps://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases\n\nDeaths, 1,283 = 545,273\n\nVaccines\n\nhttps://covid.cdc.gov/covid-data-tracker/#vaccinations\n\nFirst dose, 91,707,729 (27.6%)\n\nSecond dose, 50,141,769 (15.1)\n\nBrazil\n\nhttps://www.upi.com/Top_News/World-News/2021/03/27/Brazil-COVID-19-surge-new-variant/5401616866503/\n\nhttps://www.wsj.com/articles/covid-19-variant-rages-in-brazil-posing-global-risk-11616845889\n\nPopulation, 213 million\n\nDeaths, + 3,000 (per day)\n\nAndr\u00e9ia Cruz, emergency-ward nurse, Porto Alegre\n\nWe\u2019re in the trenches here, fighting a war\n\nP.1 strain, now in 20 countries\n\nManaus variant\n\nIndustrial hub, truck route\n\nMost prevalent variant in Brazil\n\nNew York, found last week\n\nUp to 2.2 times more contagious\n\nUp to 61% more able to reinfect people\n\n? increased mortality\n\nPorto Alegre\n\nP.1 at least 60%\n\nHospitals overwhelmed\n\nDoctors report younger patients\n\nDoctors report fitter patients getting sick\n\nDeaths in Brazil (WSJ analysis)\n\nUnder 60 previous peak, 26% of deaths\n\nUnder 60s, this peak, 30% of deaths \n\nDiego Montarroyos Sim\u00f5es, intensive-care doctor, Recife\n\nWe\u2019re seeing patients who aren\u2019t obese, who have no comorbidities, who are not old but, even so, the virus just overwhelms them\n\nProblems\n\nUS, widespread complacency\n\nFully vaccinated in Brazil, 1.9%\n\n? further P.1 mutations\n\nWilliam Hanage, Harvard University epidemiologist\n\nThere is a rush to declare this pandemic is over, and it\u2019s not\n\nI dread to think what will happen when P.1 manages to get to places that are not likely to get vaccinated for quite some time\n\nMost daily cases per capita ever \n\nUruguay, Brazil, Chile, Peru, Colombia\n\nFelipe Naveca, Oswaldo Cruz Foundation\n\nhttps://portal.fiocruz.br/en\n\nIf we don\u2019t stop the virus circulating, it won\u2019t stop evolving\n\nPeru\n\n40% of infections are P.1\n\nCurrent vaccines, efficacy against P.1?\n\nPreliminary studies\n\nYes, but possible/probably reduced efficacy", "link": "https://www.youtube.com/watch?v=sni7e-2oGZk", "date_published": "2021-03-28 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Dr Lisa Fitzpatrick in Washington DC", "description": "Dr. Lisa Fitzpatrick (@GrapevineHealth) is an infectious disease physician and CDC-trained epidemiologist. She creates #healthliteracy and #health video to help people understand their bodies and navigate the health care system. Subscribe to her YouTube channel.  \n\nLisa's YouTube channel, https://www.youtube.com/results?search_query=grapevine+health", "link": "https://www.youtube.com/watch?v=mF_zqqFhGyk", "date_published": "2021-03-28 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "New antiviral drug in trials", "description": "Novel oral antiviral for SARS-CoV-2 progresses in Phase I trial, Protease inhibitor\n\nhttps://www.europeanpharmaceuticalreview.com/news/148536/novel-oral-antiviral-for-sars-cov-2-progresses-in-phase-i-trial/\n\nBackground science\n\nViral proteases are enzymes, endopeptidases\n\nEncoded by the genetic material (DNA or RNA) of viral pathogens\n\nCatalyze cleavage of specific peptide bonds in viral precursors\n\nThese proteolytic events are essential for the completion of the viral infectious cycle\n\nProtease inhibitors, bind to a viral enzyme, called a protease\n\nPrevent the virus from replicating\n\nProtease inhibitors, used to treat HIV and hepatitis C\n\nAssess tolerability and safety of multiple ascending doses of PF-07321332\n\nPhase I study, healthy adults \n\nRandomised, double-blind, sponsor-open, placebo-controlled, single- and multiple-dose escalation study in healthy adults evaluating the safety, tolerability and pharmacokinetics of PF-07321332.\n\nProtease inhibitor, demonstrated potent in vitro antiviral activity against SARS-CoV-2 and other coronaviruses. \n\nCould be prescribed orally at the first sign of infection\n\nPfizer also investigating an intravenously administered protease inhibitor, PF-07304814, in hospitalised patients with COVID-19.\n\nNovember??", "link": "https://www.youtube.com/watch?v=qXrNQa6Vb9c", "date_published": "2021-03-27 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Viral mutation and evolution", "description": "Viral evolution\n\nadenine, cytosine, uracil, guanine\n\nDarwinian evolution\n\nSpecies undergo random mutation\n\nMaking most less fit\n\nBut making a few more fit\n\nFit means compete, survive, reproduce\n\nNatural selection will \u2018select\u2019 the more fit\n\nViruses usually become less virulent over time\n\nIncreased virulence / transmissibility\n\nMutations that increase transmissibility\n\nMutations that can avoid antibodies\n\nMutations that can avoid vaccination defences", "link": "https://www.youtube.com/watch?v=h9irEbq43Qc", "date_published": "2021-03-27 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]